The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Full Deal Summary

Regenerative medicine company Asterias Biotherapeutics Inc. netted $9.9mm through the registered direct offering of 4mm common shares at $2.60 (a 21% discount). Chardan was the placement agent. The company will use the proceeds to fund continued development of its Phase I/II ASTOPC1 stem cell therapy candidate for spinal cord injury. Asterias also has in its pipeline cell therapy compounds for leukemia (Phase II) and lung cancer (preclinical).

+ Show All | – Hide All


Click a figure for comparable deals.

Potential Deal Value $9.90mm
Transactions 1 of 1 (10/2017)
Equity $9.90mm
Total Line Value $9.90mm
Price/Share $2.60
# Shares 4mm
Shares Outstanding 54.05mm
Post-Money Valuation $140.53mm
Premium (Disc) as % -21%
Gross Proceeds $10.40mm
Net Proceeds $9.90mm

Deal Information

Click a keyword for comparable deals.

Deal Industry Biotechnology
Gene Therapy, Cell Therapy
Deal Status Final
Deal Type Financing
Private Investment in Public Equity
Private Placement